Literature-cited clinical use of haptoglobin in Japan
Clinical condition . | Subjects/controls . | Haptoglobin dose . | Primary finding (intention of treatment) . | Reference . |
---|---|---|---|---|
Cardiopulmonary bypass surgery | 16/21 | 6 g | Prevention of acute renal failure | Hashimoto et al87 |
14/0 | 4 g | Tanaka et al88 | ||
Coronary artery bypass grafting in a patient with β-thalassemia and severe hemolysis | Single case report | Horai et al89 | ||
Peripheral blood stem cell transplantation | Single case report | 3 g | Prevention of acute renal failure | Tsuda et al90 |
Hemolytic transfusion reaction | Single case report | 6 g | Prevention of acute renal failure | Homann et al91 |
Massive transfusion | 16/34 | 6 g | Undetermined benefit | Gando et al92 |
Extracorporeal circulation | 10/10 | 6 g | Prevention of acute renal failure | Kanamori et al93 |
HELLP syndrome | 17/17 | 3 g | Prevention of acute renal failure | Yamamoto et al94 |
ABO-incompatible BM transplantation | Two patient case reports | 11 g | Prevention of acute renal failure | Ito et al95 |
Thermal injury | Single case report (repeated, large-dose therapy) | > 20 g | Improved outcome | Imaizumi et al96 |
Prevention of hemoglobinuria and acute renal failure | Yoshioka et al97 | |||
Glucose-6-phosphate dehydrogenase deficiency | Single patient case report (24-mo-old boy) | 8.5 g | Prevention of hemoglobinuria | Ohga et al98 |
Adult patent ductus arteriosus, coil embolization | Single patient case report | 45 g | Prevention of hemoglobinuria | Eda et al99 |
Clinical condition . | Subjects/controls . | Haptoglobin dose . | Primary finding (intention of treatment) . | Reference . |
---|---|---|---|---|
Cardiopulmonary bypass surgery | 16/21 | 6 g | Prevention of acute renal failure | Hashimoto et al87 |
14/0 | 4 g | Tanaka et al88 | ||
Coronary artery bypass grafting in a patient with β-thalassemia and severe hemolysis | Single case report | Horai et al89 | ||
Peripheral blood stem cell transplantation | Single case report | 3 g | Prevention of acute renal failure | Tsuda et al90 |
Hemolytic transfusion reaction | Single case report | 6 g | Prevention of acute renal failure | Homann et al91 |
Massive transfusion | 16/34 | 6 g | Undetermined benefit | Gando et al92 |
Extracorporeal circulation | 10/10 | 6 g | Prevention of acute renal failure | Kanamori et al93 |
HELLP syndrome | 17/17 | 3 g | Prevention of acute renal failure | Yamamoto et al94 |
ABO-incompatible BM transplantation | Two patient case reports | 11 g | Prevention of acute renal failure | Ito et al95 |
Thermal injury | Single case report (repeated, large-dose therapy) | > 20 g | Improved outcome | Imaizumi et al96 |
Prevention of hemoglobinuria and acute renal failure | Yoshioka et al97 | |||
Glucose-6-phosphate dehydrogenase deficiency | Single patient case report (24-mo-old boy) | 8.5 g | Prevention of hemoglobinuria | Ohga et al98 |
Adult patent ductus arteriosus, coil embolization | Single patient case report | 45 g | Prevention of hemoglobinuria | Eda et al99 |